• / Free eNewsletters & Magazine
  • / My Account
Home>Vivet’s First Gene Therapy Product, VTX 801 for Wilson’s Disease, Receives European and US Orphan Drug Designation

Vivet’s First Gene Therapy Product, VTX 801 for Wilson’s Disease, Receives European and US Orphan Drug Designation

3party Content

Tue, 26 Sep 2017

Vivet’s First Gene Therapy Product, VTX 801 for Wilson’s Disease, Receives European and US Orphan Drug Designation

©2017 Morningstar Advisor. All right reserved.